{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sha X"],"funding":["Double First Class Foundation of China Pharmaceutical University","China Postdoctoral Science Foundation","the National Natural Science Foundation of China"],"pagination":["224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11924601"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Inducing ferroptotic cell death has been recognized as a promising approach in cancer therapy. However, ferroptosis can provoke tumor infiltration by myeloid-derived suppressor cells (MDSCs) through HMGB1 secretion, causing a tumor suppressive immune response. On the other hand, ferroptosis also occurs the immune cells due to its non-selective properties, which can compromise anti-tumor immunity. To address these challenges, a two-pronged approach is proposed, encompassing selectively triggered ferroptosis in tumor cells and HMGB1 blockade, aimed at eliciting systemic anti-tumor immunity and alleviating immunosuppression. Herein, GSH-specific driven nanoplatform is composed of uniform FeOOH nanospindles coated with tetrasulfide bond-bridged mesoporous organosilica (DMOS) shell, and loaded "],"journal":["Journal of nanobiotechnology"],"pubmed_title":["Multifunctional glycyrrhizic acid-loaded nanoplatform combining ferroptosis induction and HMGB1 blockade for enhanced tumor immunotherapy."],"pmcid":["PMC11924601"],"funding_grant_id":["CPUQNJC22_03","2021TQ0158, 2022M711678","82372019"],"pubmed_authors":["Zhong N","Liu Y","He D","Sha X","Wang C","Lu Y","Wang S","Lu S","Jin Y","Zhang Q","Tang Y"],"additional_accession":[]},"is_claimable":false,"name":"Multifunctional glycyrrhizic acid-loaded nanoplatform combining ferroptosis induction and HMGB1 blockade for enhanced tumor immunotherapy.","description":"Inducing ferroptotic cell death has been recognized as a promising approach in cancer therapy. However, ferroptosis can provoke tumor infiltration by myeloid-derived suppressor cells (MDSCs) through HMGB1 secretion, causing a tumor suppressive immune response. On the other hand, ferroptosis also occurs the immune cells due to its non-selective properties, which can compromise anti-tumor immunity. To address these challenges, a two-pronged approach is proposed, encompassing selectively triggered ferroptosis in tumor cells and HMGB1 blockade, aimed at eliciting systemic anti-tumor immunity and alleviating immunosuppression. Herein, GSH-specific driven nanoplatform is composed of uniform FeOOH nanospindles coated with tetrasulfide bond-bridged mesoporous organosilica (DMOS) shell, and loaded ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-01T05:43:35.551Z","creation":"2025-04-04T14:48:04.965Z"},"accession":"S-EPMC11924601","cross_references":{"pubmed":["40108690"],"doi":["10.1186/s12951-025-03307-z"]}}